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Allogeneic hematopoietic stem cell transplantation (allo-SCT) using post-transplant cyclophosphamide
(PTCy) is increasingly performed. We conducted a multicenter phase II study to evaluate the safety and ef-
ﬁcacy of PTCy-based HLA-haploidentical peripheral blood stem cell transplantation (PTCy-haploPBSCT) after
busulfan-containing reduced-intensity conditioning. Thirty-one patients were enrolled; 61% patients were
not in remission and 42% patients had a history of prior allo-SCT. Neutrophil engraftment was achieved in 87%
patients with a median of 19 days. The cumulative incidence of grades II to IV and III to IV acute graft-versus-
host disease (GVHD) and chronic GVHD at 1 year were 23%, 3%, and 15%, respectively. No patients developed
severe chronic GVHD. Day 100 nonrelapse mortality (NRM) rate was 19.4%. Overall survival, relapse, and
disease-free survival rates were 45%, 45%, and 34%, respectively, at 1 year. Subgroup analysis showed that
patients who had a history of prior allo-SCT had lower engraftment, higher NRM, and lower overall survival
than those not receiving a prior allo-SCT. Our results suggest that PTCy-haploPBSCT after busulfan-containing
reduced-intensity conditioning achieved low incidences of acute and chronic GVHD and NRM and stable
donor engraftment and low NRM, particularly in patients without a history of prior allo-SCT.
 2015 American Society for Blood and Marrow Transplantation.INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-
SCT) is a potentially curative treatment for patients with
hematological malignancies. HLA-matched related or unre-
lated donors are the ﬁrst choice but are not always available
for all patients. Alternative donors who share a single HLA
haplotype (HLA-haploidentical donors) with recipients areedgments on page 1651.
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ty for Blood and Marrow Transplantation.nearly always available, but HLA-haploidentical SCT (hap-
loSCT) is associatedwith high incidences of graft-versus-host
disease (GVHD) and graft rejection [1-3]. Over the last few
decades, several strategies have been developed to overcome
HLA barriers in haploSCT.
The most popular strategy has been T cell depletion of
peripheral blood stem cell (PBSC) grafts mostly by immu-
nomagnetic CD34-positive selection [4]. However, this
strategy is associated with an increased risk of severe
opportunistic infections and nonrelapse mortality (NRM)
early after haploSCT.
More recently, T cellereplete haploSCT has been
developed by using post-transplant cyclophosphamide
Table 1
Patient Characteristics
Characteristic Value
Median age, yr (range) 48 (21-65)
Sex, n (%)
Male 22 (71.0)
Female 9 (29.0)
Diagnosis, n (%)
Acute myeloid leukemia 17 (54.8)
Acute lymphoblastic leukemia/
lymphoblastic lymphoma
8 (25.8)
Myelodysplastic syndrome/
myeloproliferative neoplasms
4 (12.9)
Diffuse large B cell lymphoma 1 (3.2)
Follicular lymphoma 1 (3.2)
Disease status, n (%)
CR1 7 (22.6)
CR2 or subsequent CR 5 (16.1)
Not in remission 19 (61.3)
Reﬁned DRI, n (%)
Very high 11 (35.5)
High 11 (35.5)
Intermediate 8 (25.8)
Low 1 (3.2)
HCT-CI, n (%)
0 19 (61.3)
1-2 9 (29.0)
3-4 3 (9.7)
History of prior allo-SCT, n (%)
No 18 (58.1)
Yes 13 (41.9)
Median duration from diagnosis to
haploPBSCT, mo (range)
12 (3-72)
CR1 indicates ﬁrst complete remission; CR2, second complete remission; CR,
complete remission; HCT-CI, hematopoietic cell transplantationespeciﬁc
comorbidity index.
Table 2
Donor and Graft Characteristics
Characteristic Value
HLA match
(GVH direction)
4/8 18 (58.1%)
5/8 12 (38.7%)
6/8 1 (3.2%)
(HVG direction)
4/8 20 (64.5%)
5/8 9 (29.0%)
6/8 2 (6.5%)
Donor relationship
Parent 7 (22.6%)
Sibling 9 (29.0%)
Child 14 (45.1%)
Other 1 (3.2%)
Cytomegalovirus serostatus
DþRþ 24 (77.4%)
DRþ 5 (16.1%)
DþR 1 (3.2%)
DR 0 (0%)
NA 1 (3.2%)
Cell dose, median (range)
CD34 (106/kg) 4.0 (1.4-10.5)
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depletion of alloreactive T cells, as demonstrated in mouse
studies [10-13]. Remarkably, the incidence of acute GVHD,
chronic GVHD, and NRM after PTCy-based haploidentical
bone marrow transplantation (PTCy-haploBMT) after
reduced-intensity conditioning (RIC) appears to be equiva-
lent to those after HLA-matched SCT [5,14]. However, relapse
remains a major problem after PTCy-haploBMT with RIC.
In an attempt to decrease relapse, we added busulfan (BU)
to the original nonmyeloablative platform consisting of ﬂu-
darabine (Flu), cyclophosphamide (Cy), and 2 Gy total body
irradiation (TBI) developed by Luznik et al. [5]. In addition,
PBSC grafts were used instead of bone marrow grafts.
Because of the greater content of T cells in PBSC grafts
compared with bone marrow grafts, PBSC transplantation
(PBSCT) may be associated with better engraftment and
disease control [15,16]. Herein we report the results of a
prospective, multicenter, phase II study to evaluate the safety
and efﬁcacy of PTCy-based HLA-haploidentical PBSCT (PTCy-
haploPBSCT) after BU-containing RIC.
METHODS
Study Design
This prospective, multicenter, phase II study (UMIN-CTR
UMIN000010316) was conducted by the Japan Study Group for Cell Therapy
and Transplantation. Patients from ages 15 to 65 with hematological ma-
lignancies who had no HLA-matched related or unrelated available donors
were enrolled. The institutional review board of each participating institu-
tion approved the study protocol, and written informed consent was ob-
tained from all patients in accordance with the Declaration of Helsinki.
The primary endpoint was the incidence of NRM at 100 days. The ex-
pected NRM was estimated to be 30% and the threshold NRM, determined
according to previous studies [17], was set to be 60%. Secondary endpoints
included overall survival (OS), disease-free survival (DFS), the incidence of
engraftment, acute GVHD, chronic GVHD, relapse, and incidence of nonin-
fectious fever early after PTCy-haploPBSCT. The required sample size was 19
eligible patients for an 80% power to detect a 30% difference in the NRM at
100 days from the threshold with a 1-sided Type I error of .05. The planned
sample size was 21 with the expectation that 10% would be ineligible.
Eligibility Criteria
Eligibility criteria were as follows: ages 15 to 65 years, diagnosis of
hematological malignancies, a good performance status (Eastern Coopera-
tive Oncology Group performance status of 0 to 2), and good organ function
(bilirubin< 2.0 mg/dL, aspartate/alanine aminotransferases< 3 times upper
limit of normal, creatinine clearance > 30 mL/min, cardiac ejection fraction
> 50%, and peripheral capillary oxygen saturation (SpO2) at room air> 95%).
Patients who had antibodies targeting mismatched donor HLAs (donor-
speciﬁc antibodies) were excluded.
Conditioning Regimens and GVHD Prophylaxis
The conditioning regimen consisted of Flu (30 mg/m2/day on days 6
to 2), Cy (14.5 mg/kg/day on days 6 and 5), BU (3.2 mg/kg/day on
days 3 and 2), and TBI (2 Gy on day 1). GVHD prophylaxis consisted of
Cy (50 mg/kg/day on days 3 and 4), tacrolimus (days 5 to 180), and myco-
phenolate mofetil (days 5 to 60).
Deﬁnitions
Disease risk of the patients was determined according to the reﬁned
Disease Risk Index (DRI) [18]. Neutrophil engraftment was deﬁned as an
absolute neutrophil count of .5  109/L for 3 consecutive days. Platelet
engraftment was deﬁned as a platelet count > 20  109/L without trans-
fusion for the 7 preceding days. Time to engraftment was deﬁned as the time
required to reach the ﬁrst day of engraftment. Acute and chronic GVHDwere
deﬁned and graded according to standard criteria [19,20]. Time to relapse/
progressive diseasewas calculated fromPBSCT to the day of the documented
event. OS was calculated from the day of PBSCT, with patients alive at the
time of last follow-up censored. NRMwas deﬁned as death due to any cause
of death without relapse. Noninfectious fever was deﬁned as fever (>38C)
without clinical or microbiological documentation of infection.
Statistical Analysis
The primary endpoint was the incidence of NRM at 100 days. Cumula-
tive incidence curves were used in a competing-risks setting to calculate theprobabilities of neutrophil recovery, acute and chronic GVHD, relapse, and
NRM. For neutrophil recovery, competing events were death or relapse
before engraftment [21]. For GVHD, death without GVHD and relapse were
competing events. For relapse, death without relapse was the competing
event, and for NRM, relapse was the competing event. Unadjusted OS and
event-free survival were estimated by Kaplan-Meier curves. Differences in
NRM and OS between subgroups were evaluated using Gray’s test and a log-
rank test, respectively [22]. P < .05 is considered as signiﬁcant. All statistical
analyses were performed with EZR [23].
Figure 1. Time course of body temperature early after haploPBSCT. Data
represent mean  standard deviation of the maximum temperature of each
day.
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Patient Characteristics
Patient characteristics are summarized in Table 1. Thirty-
one patients with a median age of 48 (range, 21 to 65) were
enrolled in this study between May 2013 and April 2014.
Pateitn diagnoses included acute myeloid leukemia (n ¼ 17),
acute lymphoblastic leukemia/lymphoblastic lymphoma
(n ¼ 8), myelodysplastic syndrome/myeloproliferative neo-
plasms (n ¼ 4), and lymphoma (n ¼ 2). According to the
reﬁned DRI [18], patients were classiﬁed as low risk (n ¼ 1),
intermediate risk (n ¼ 8), high risk (n ¼ 11), and very high
risk (n ¼ 11). Nineteen patients (61%) were not in remission,
and 13 patients (42%) had a history of prior allo-SCT once
(n ¼ 10) or twice (n ¼ 3). For these patients, haploPBSCT was
undertaken for relapse. Transplantation-related donor and
recipient information is shown in Table 2. The median
number of CD34þ cells was 4.0  106/kg (range, 1.4 to 10.5).Noninfectious Fever Early after HaploPBSCT
All patients developed high fever without evidence of
documented infection with a peak at day 3 and quickly
resolved after administration of PTCy (Figure 1). No patients
received corticosteroids before administration of PTCy.Engraftment
Neutrophil engraftment was achieved in 27 patients
(87%) at a median of 19 days (range, 15 to 27) (Figure 2A). The
median time to platelet engraftment was 35 days (range, 13Figure 2. Engraftment. Cumulative incidences are shown for (to 224) (Figure 2B). Peripheral blood or bone marrow sam-
ples were collected on days 30 post-transplant, and donor
chimerism of whole nucleated cells and CD3þ cells were
determined. Complete donor chimerism of both whole cells
and CD3þ cells deﬁned by >95% donor chimerism was ach-
ieved in all patients. Four patients (13%) were not engrafted.
Two patients died before neutrophil recovery because of
sepsis on day 17 or sinusoidal obstructive disease on day 34.
One patient relapsed after PBSCT, and 1 patient achieved
engraftment after rescue transplantation.
Acute and Chronic GVHD
The cumulative incidence of grades II to IV and III to IV
acute GVHD at 100 days was 23% (95% conﬁdence interval
[CI], 10% to 39%) and 3% (95% CI, 0% to 14%), respectively
(Figure 3A). Cumulative incidence of chronic GVHD was 15%
(95% CI, 4% to 32%) at 1 year (Figure 3B). One patient devel-
opedmild chronic GVHD, and 2 patients developedmoderate
chronic GVHD. No patients developed severe chronic GVHD.
NRM and Relapse
Rates of NRMwere 19% (95% CI, 8% to 35%) at 100 days and
23% (95% CI, 10% to 39%) at 1 year (Figure 4A). Cumulative
incidence of relapse was 19% (95% CI, 8% to 35%) at 100 days
and 45% (95% CI, 25% to 64) at 1 year (Figure 4A).
OS, DFS, and Cause of Death
After a median follow-up of 287 days (range, 226 to 517),
15 patients (48%) were alive. Rates of OS were 74% (95% CI,
55% to 86%) at 100 days and 45% (95% CI, 26% to 62%) at 1
year. Rates of DFS were 62% (95% CI, 42% to 76%) at 100 days
and 34% (95% CI, 16% to 53%) at 1 year (Figure 4B). Nine pa-
tients (29%) died of relapse and 7 patients (23%) died of NRM
(Table 3).
Engraftment, NRM, and OS According to the History of
Prior Allo-SCT
Subgroup analysis showed that patients who had a his-
tory of prior allo-SCT (n ¼ 13) had lower engraftment (69%
versus 100%, P ¼ .04; Figure 5A), higher NRM (39% versus
11%, P ¼ .07; Figure 5B), and lower OS (29% versus 56%,
P ¼ .05; Figure 5C) than those without a history of prior allo-
SCT (n ¼ 18). In 8 patients who had no prior allo-SCT and
were transplanted in remission, 1 patient (13%) died of NRM,
and 2 patients (25%) relapsed. In 10 patients who had no
prior history of prior SCT and were not transplanted in
remission, 1 patient (10%) died of NRM and 7 patients (70%)A) neutrophil engraftment and (B) platelet engraftment.
Figure 3. GVHD. Cumulative incidences are shown for (A) grades II to IV (solid line) and grades III to IV (dashed line) acute GVHD and (B) chronic GVHD.
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were transplanted in remission, 2 patients (50%) died of NRM
and 2 patients (50%) relapsed. In 9 patients who had a history
of prior allo-SCT and were not transplanted in remission, 3
patients (33%) died of NRM and 4 patients (57%) relapsed.Relapse, DFS, and OS According to the Reﬁned DRI
Nine patients (29%) were classiﬁed as low/intermediate
risk and 22 patients (71%) as high/very high risk according to
the reﬁned DRI [18]. The incidences of relapse at 1 year were
0% in patients with low/intermediate risk and 61% in patients
with high/very high risk. The incidences of OS and DFS at 1
year were 67% and 67%, respectively, in patients with low/
intermediate risk and 37% and 22%, respectively, in patients
with high/very high risk.DISCUSSION
Luznik et al. [5,12] pioneered a novel GVHD prophylaxis
using PTCy in the haploidentical setting based on animal
studies on tolerance induction by PTCy. Their initial protocols
used a nonmyeloablative regimen and bone marrow as the
source of hematopoietic stem cells. This is because a com-
bination of HLA-mismatch, myeloablative conditioning, and
PBSCT represents the highest risk for acute GVHD [24,25].
Although PTCy-haploBMT after a nonmyeloablative regimen
ensures good GVHD controls, relapse remains a problem. We
developed a strategy in which BU was added to the Johns
Hopkins’ nonmyeloablative regimen and PBSCs were used as
the stem cell source in the setting of PTCy-haploSCT toFigure 4. NRM, relapse, OS, and DFS. Cumulative incidences are shown for (A) NRM (s
and DFS (dashed line).augment disease control and prospectively demonstrated
that this strategy was feasible and safe.
Several groups have developed PTCy-haploSCT after
BU-based myeloablative conditioning. Solomon et al. [26]
reported the results of PTCy-haploPBSCT after myeloa-
blative conditioning consisting of Flu (125 to 180 mg/m2), Cy
(29 mg/kg), and BU (440 to 520 mg/m2). The incidences of
relapse, DFS, and OS at 1 year were 40%, 50%, and 69%,
respectively. Raiola et al. [27] reported the result of PTCy-
haploBMT after myeloablative conditioning consisting of
Flu (150 mg/m2), BU (3.2 to 9.6 mg/kg), and thiotepa (10 mg/
kg) or Flu (120 mg/m2) and TBI (9.9 to 12 Gy). The incidences
of relapse, DFS, and OS at 18 months were 22%, 51%, and
62%, respectively. Our study used RIC regimen containing BU
(6.4 mg/kg) and included larger numbers of patients not in
remission and those with a history of prior allo-SCT than
other studies; therefore, it is not surprising that a 1-year
relapse rate of 45% was higher than that of other studies.
Nonetheless, 1-year DFS and OS rates of 34% and 45%,
respectively, appear to be lower than in other studies, sug-
gesting that the use of a RIC regimen in the setting of PTCy-
haploPBSCT is associated with increased relapse but reduced
treatment-related mortality. The myeloablative dose used in
the BU-based regimen, however, is being increasingly stud-
ied in the setting of PTCy-haploSCT [26,27].
GVHD prophylaxis using PTCy has been tested by several
groups in the setting of haploPBSCT [26,28-30]. In these
studies engraftment was achieved in 94% to 100%, and the
incidences of grades II to IV acute GVHD were 33% to 53%. In
general, it seems so far that PBSCT is associated with anolid line) and relapse (dashed line). Probabilities are shown for (B) OS (solid line)
Table 3
Causes of Death
Causes of Death First SCT Second/Third SCT Total
Relapse 5 4 9
NRM
Sinusoidal obstruction
syndrome
0 2 2
Acute respiratory
distress syndrome
0 1 1
Infection 1 1 2
Multiple organ failure 1 1 2
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GVHDwhen comparedwith PTCy-haploBMT [5]. In our study
all patients without a history of prior SCT achieved engraft-
ment. The incidence of GVHDwas lower than that from other
studies of PTCy-haploPBSCT (grades II to IV acute GVHD, 23%
versus 33% to 53%) [26,28-30]. This may be due to a longer
duration of mycophenolate mofetil administration of 60 days
in our study versus 35 days in the others and/or genetic
homogeneity in the Japanese population. The incidence of
chronic GVHD was remarkably low (15%), similar to previous
reports of PTCy-haploBMT [5]. Furthermore, the absence of
severe chronic GVHD was noteworthy, although a median
follow-up of 287 days was not sufﬁcient to assess the inci-
dence of chronic GVHD.
Noninfectious fever developed in all patients with a peak
at day 3 but was quickly relieved by PTCy administration.
Noninfectious fever is the major manifestation of hap-
loimmunostorm syndrome seen in HLA-mismatched cellular
therapy and is associated with vigorous proliferation of
alloreactive T cells and subsequent inﬂammatory milieu in
the absence of post-transplant immunosuppressants untilFigure 5. Engraftment, NRM, and OS according to the history of prior allo-SCT. (A) Cum
(C) Probability of OS.day 5 despite HLA haplotype mismatch [31]. This syndrome
is likely to be more frequent after PTCy-haploPBSCT than
PTCy-haploBMT [26,32] and as frequent after PTCy-based
HLA-matched BMT [32], suggesting that haploPBSCT is a
risk for haploimmunostorm syndrome. Interestingly, Colvin
et al. [33] suggested that haploimmunostorm syndrome
conferred an antitumor effect [33]. It is intriguing to deter-
mine the impact of haploimmune syndrome on disease
control in the setting of PTCy-haploPBSCT. Administration of
immunosuppressants before PTCy administration may
theoretically diminish the effect of PTCy [34]. However, this
hypothesis has never been tested clinically, and in fact
tacrolimus was given before PTCy in several studies [27].
The cumulative incidence of relapse was 45% at 1 year in
our study. Despite the fact that our cohort included 61% of
patients not in remission and 42% of patients having a history
of prior allo-SCT, the relapse rate was equivalent to that from
previous studies of PTCy-haploBMT, in which most patients
were in remission without a history of prior allo-SCT [5]. In
our study only 2 of 8 patients relapsed, who received PTCy-
haploPBSCT in remission without prior history of allo-SCT.
Recently, McCurdy et al. [35] reported the risk-stratiﬁed
outcomes of PTCy-haploBMT after nonmyeloablative condi-
tioning using a reﬁned DRI. Cumulative incidences of 1-year
relapse were 17%, 38%, and 58% in low, intermediate, and
high/very high risk patients, respectively. In our study,
although a 61% relapse rate of high-risk patients was
equivalent, 0% relapse rate of low/intermediate risk patients
was lower compared with McCurdy’s study. A combination
of RIC and PBSCT in the setting of PTCy-haploSCT might be
promising to reduce relapse in patients with low/interme-
diate risk, but efﬁcacy of this strategy needs to be investi-
gated in a larger study involving a larger number of a moreulative incidence of neutrophil engraftment. (B) Cumulative incidence of NRM.
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remission. However, for patients with advanced disease, a
myeloablative conditioning regimen may provide better
disease control, given high rates of relapse in these patients.
A unique aspect of this study was the inclusion of a large
proportion of patients with a history of prior allo-SCT.
Because most previous studies of PTCy-haploSCT did not
include patients with a history of prior allo-SCT [5,26,27],
little data regarding outcomes of PTCy-haploSCT used as a
second or third allo-SCT are available in literature. Remark-
ably, 31% of such patients failed to achieve engraftment, and
NRM reached 33%. On the other hand, all patients without a
history of prior allo-SCT achieved sustained engraftment and
NRM was only 11%, which was comparable with reported
incidences of 15% NRM in PTCy-haploBMT [5]. High inci-
dence of graft failure in patients with a history of prior allo-
SCT suggests that recipient T cells derived from prior SCT
donors are associated with rejection. Notably, 3 of 4 patients
who experienced graft rejection had a history of prior SCT
from HLA-mismatched donors and had developed GVHD
after a prior SCT, suggesting that host-reactive memory T
cells derived from the previous donor were associated with
rejection of PBSCs from a haploidentical family donor who
shared mismatched HLA antigens with recipients. This is still
speculative but may be supported by a recent study
demonstrating that antigen-speciﬁc memory T cells survive
PTCy [36]. Thus, outcomes of PTCy-haploPBSCT in patients
who had a history of prior allo-SCT are not satisfactory, as in
other transplant modalities. However, the numbers of pa-
tients are small, and the results of our subgroup analysis
should be conﬁrmed in larger studies.
In conclusion, our results suggest that PTCy-haploPBSCT
after BU-containing RIC achieves stable donor engraftment
and low incidences of acute and chronic GVHD. NRM and the
incidence of GVHD were remarkably low; particularly, there
was no extensive chronic GVHD. Given the promising results
of GVHD and NRM, we are now conducting a phase II study of
PTCy-haploPBSCT using myeloablative conditioning in pa-
tients without prior allo-SCT.ACKNOWLEDGMENTS
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